Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced NSCLC With EGFR Mutation”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT03420079
What this trial is testing

A Phase I Study of FCN-411 in Advanced Non-small Cell Lung Cancer Chinese Patients With EGFR Positive Mutation

Who this might be right for
Lung Cancer
Ahon Pharmaceutical Co., Ltd. 90
Not applicableStudy completedNCT03370770
What this trial is testing

Afatinib Osimertinib Sequencing NIS

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 204
Testing effectiveness (Phase 2)Looking for participantsNCT03175224
What this trial is testing

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Who this might be right for
Solid TumorsAdvanced CancerRenal Cancer+15 more
Apollomics Inc. 497
Testing effectiveness (Phase 2)Ended earlyNCT02954523
What this trial is testing

Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations

Who this might be right for
EGFR Gene MutationNonsmall Cell Lung Cancer
Chul Kim 10
Not applicableStudy completedNCT02777658
What this trial is testing

PANORAMA - Real World Molecular Testing, Treatment Patterns, and Clinical Outcomes EGFR Mutation-Positive NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell Lung
AstraZeneca 169
Large-scale testing (Phase 3)UnknownNCT02633189
What this trial is testing

Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer

Who this might be right for
Non-squamous Non-small Cell Lung Cancer
National Cancer Institute, Naples 200
Not applicableStudy completedNCT01947868
What this trial is testing

Evaluation of Symptoms Improvement in NSCLC Patients With First-Line Therapy of EGFR Tyrosine Kinase Inhibitor

Who this might be right for
Non-Small-Cell Lung Cancer
AstraZeneca 346
Large-scale testing (Phase 3)Active Not RecruitingNCT04487080
What this trial is testing

Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC 1,074
Early research (Phase 1)Study completedNCT02926768
What this trial is testing

Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors

Who this might be right for
Lung NeoplasmsCarcinoma, Non-Small-Cell LungLung Diseases+1 more
Checkpoint Therapeutics, Inc. 136
Testing effectiveness (Phase 2)UnknownNCT03126799
What this trial is testing

Tarceva vs. Avastin+Tarceva for Advanced NSCLC With EGFR m(+)

Who this might be right for
EGFR Positive Non-small Cell Lung Cancer
National Cancer Center, Korea 128
Testing effectiveness (Phase 2)Looking for participantsNCT06348927
What this trial is testing

Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLC

Who this might be right for
Non-Small Cell Lung Cancer
Hunan Province Tumor Hospital 52
Post-approval studies (Phase 4)Study completedNCT01287754
What this trial is testing

Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations

Who this might be right for
Non-Small Cell Lung Cancer
Hoffmann-La Roche 24
Not applicableActive Not RecruitingNCT03969823
What this trial is testing

Whole Genomic Landscape of Advanced EGFR-mutant NSCLC

Who this might be right for
Locally Advanced or Metastatic NSCLC
Seoul National University Hospital 148
Early research (Phase 1)Ended earlyNCT05578092
What this trial is testing

MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway

Who this might be right for
Solid TumorAdvanced Solid TumorNon Small Cell Lung Cancer+1 more
Mirati Therapeutics Inc. 64
Testing effectiveness (Phase 2)UnknownNCT05507606
What this trial is testing

Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations

Who this might be right for
Non Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital 50
Early research (Phase 1)Study completedNCT02163733
What this trial is testing

Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer

Who this might be right for
Advanced Non Small Cell Lung CancerAdvanced (Inoperable) Non Small Cell Lung Cancer
AstraZeneca 38
Not applicableStudy completedNCT05419700
What this trial is testing

A Spanish Medical Record Review of Clinical Characteristics and Outcomes in Non-small Cell Lung Cancer Participants With EGFR Exon 20 Insertion

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Takeda 76
Testing effectiveness (Phase 2)Looking for participantsNCT06343064
What this trial is testing

Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI

Who this might be right for
Non-Small-Cell Lung Cancer
Avistone Biotechnology Co., Ltd. 156
Testing effectiveness (Phase 2)Looking for participantsNCT05271916
What this trial is testing

First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)
Shanghai Chest Hospital 140
Testing effectiveness (Phase 2)UnknownNCT06590194
What this trial is testing

PH009-1 in Patients With EGFR Mutation Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Suzhou Puhe Pharmaceutical Technology Co., LTD 96
Next Page